NRx Pharmaceuticals (NASDAQ:NRXP) Updates FY 2023 Earnings Guidance

NRx Pharmaceuticals (NASDAQ:NRXP) updated its FY 2023 earnings guidance on Thursday. The company provided earnings per share guidance of -0.400–0.400 for the period, compared to the consensus earnings per share estimate of -0.370. The company issued revenue guidance of -.

NRx Pharmaceuticals Stock Down 2.9 %

Shares of NASDAQ:NRXP opened at $0.51 on Thursday. NRx Pharmaceuticals has a 12 month low of $0.22 and a 12 month high of $1.20. The company has a 50-day moving average price of $0.46 and a 200-day moving average price of $0.38.

Hedge Funds Weigh In On NRx Pharmaceuticals

Institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. grew its holdings in NRx Pharmaceuticals by 31.6% in the third quarter. Vanguard Group Inc. now owns 1,440,265 shares of the company’s stock worth $1,065,000 after purchasing an additional 345,552 shares during the period. Millennium Management LLC purchased a new stake in NRx Pharmaceuticals in the second quarter worth about $178,000. Royal Bank of Canada grew its holdings in NRx Pharmaceuticals by 135,799.2% in the second quarter. Royal Bank of Canada now owns 171,233 shares of the company’s stock worth $83,000 after purchasing an additional 171,107 shares during the period. Renaissance Technologies LLC purchased a new stake in shares of NRx Pharmaceuticals during the first quarter valued at approximately $341,000. Finally, State Street Corp grew its holdings in shares of NRx Pharmaceuticals by 1,009.1% during the first quarter. State Street Corp now owns 114,240 shares of the company’s stock valued at $280,000 after buying an additional 103,940 shares during the last quarter. 4.27% of the stock is owned by institutional investors.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutics based on N-methyl-D-aspartate platform for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned FDA-designated investigational breakthrough therapy for suicidal treatment-resistant bipolar depression and chronic pain; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of acute suicidality in depression.